Targeted Treatment in Chronic Rhinosinusitis With Nasal Polyps

Anju T. Peters, MD, MSci


July 13, 2020

Treatments in chronic rhinosinusitis with nasal polyps (CRSwNP) focus on reducing chronic type 2 inflammation. When intranasal corticosteroids, nasal saline irrigation, antibiotics, and oral steroids fail, patients move to surgery. Unfortunately, 40% of patients experience polyp regrowth following surgery.

New research in biologic therapy is showing promise. Inflammatory mediators IL-4, IL-5, IL-13, and IgE play key roles in CRSwNP. Targeting these specific inflammatory pathways may provide effective treatment options for refractory CRSwNP patients.

Dr Anju Peters discusses dupilumab, a biologic currently approved for CRSwNP, as well as other targeted biologics in development.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.